NICE recommends Eli Lilly's psoriatic arthritis drug
Eli Lilly have announced that the monoclonal antibody ixekizumab, has been recommended by NICE for use as a treatment option in England and Wales for adults with active psoriatic arthritis (PsA), after inadequate response to DMARDs (disease modifying antirheumatic drugs).
Ixekizumab was granted EU marketing authorisation in January 2018. The efficacy and safety of ixekizumab was determined from the findings of two randomized, double-blind, placebo-controlled Phase 3 studies involving 780 patients.
The NICE guidelines state that ixekizumab can be used alone or in combination with methotrexate for treating active psoriatic arthritis in adults.
“Up to 30 per cent of people with psoriasis will also develop psoriatic arthritis, a severe form of inflammatory arthritis that can cause swollen, stiff and painful joints.2 It can reduce physical function and lead to a reduction in quality of life2 so we are pleased that NICE is able to recommend this new treatment option,” said Dr. Arash Tahbaz, Senior Medical Director, Eli Lilly and Company, UK and Northern Europe.